These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16804833)

  • 1. Managing the pediatric patient and the adolescent/adult transition.
    Valentino LA; Santagostino E; Blanchette V; van den Berg M
    Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():28-31. PubMed ID: 16804833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
    Björkman S; Folkesson A; Berntorp E
    Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population.
    Young G
    Blood Coagul Fibrinolysis; 2010 Sep; 21 Suppl 1():S7-10. PubMed ID: 20855989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The next generation of hemophilia treatment specialists.
    Berntorp E; Gomperts E; Hoots K; Wong WY
    Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():39-42. PubMed ID: 16804835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future aspects of hemophilia research and care.
    Valentino LA; Scheiflinger F
    Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():32-8. PubMed ID: 16804834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary assessment of pediatric health care quality and patient safety in the United States using readily available administrative data.
    McDonald KM; Davies SM; Haberland CA; Geppert JJ; Ku A; Romano PS
    Pediatrics; 2008 Aug; 122(2):e416-25. PubMed ID: 18676529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in pediatric hematology/oncology.
    Raetz E
    Curr Opin Pediatr; 2017 Feb; 29(1):1-2. PubMed ID: 27870690
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylaxis in adults with haemophilia.
    Hay CR
    Haemophilia; 2007 Sep; 13 Suppl 2():10-5. PubMed ID: 17685918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric dose selection.
    Abernethy DR; Burckart GJ
    Clin Pharmacol Ther; 2010 Mar; 87(3):270-1. PubMed ID: 20160747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient visits to a national practice-based research network: comparing pediatric research in office settings with the National Ambulatory Medical Care Survey.
    Slora EJ; Thoma KA; Wasserman RC; Pedlow SE; Bocian AB
    Pediatrics; 2006 Aug; 118(2):e228-34. PubMed ID: 16831892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
    Fischer K; Valentino L; Ljung R; Blanchette V
    Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug therapy in pediatrics: a developing field.
    Mathis L; Rodriguez W
    Dermatol Ther; 2009; 22(3):257-61. PubMed ID: 19453350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
    Komvilaisak P; Connolly B; Naqvi A; Blanchette V
    Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of arthropathy in haemophilia: prophylaxis.
    Santagostino E; Mancuso ME
    Haemophilia; 2008 Nov; 14 Suppl 6():16-9. PubMed ID: 19134028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of haemophilic synovitis: clinical aspects.
    Hoots WK; Rodriguez N; Boggio L; Valentino LA
    Haemophilia; 2007 Nov; 13 Suppl 3():4-9. PubMed ID: 17822514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tic disorders in childhood.
    Dooley JM
    Semin Pediatr Neurol; 2006 Dec; 13(4):231-42. PubMed ID: 17178353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.